| From: jmhollen | 6/24/2005 2:52:04 PM | | | | | | GenoMed's WNV Treatment Abruptly Stopped, Patient Deteriorates
Contact: David W. Moskowitz MD FACP GenoMed, Inc. Tel. 314.983.9933
PHILADELPHIA, PA.--June 24, 2005--GenoMed (the "Company") (Pink Sheets GMED), a Next Generation DM(tm) company that uses molecular medicine to improve patient outcomes and save healthcare costs, announced today that its first presumed West Nile virus encephalitis patient is doing poorly after GenoMed's treatment was abruptly stopped last week.
The patient received two doses of GenoMed's treatment for WNV on Wednesday and early Thursday morning last week, and appeared to get better according to her mother (see 6/16/05 press release). When she was moved to the Intensive Care Unit for closer monitoring, her new Attending Physician could not be convinced of the usefulness of GenoMed's treatment, and stopped it. She has been without GenoMed's treatment for over a week now.
Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "I happened to be in Philadelphia this week for a Disease Management conference, and visited the patient in the ICU on Wednesday evening. She had evidence of decorticate posturing then, constantly shrugging her shoulders inwards. She was unresponsive to pain or verbal stimuli. The situation looked grim."
Added Dr. Moskowitz, "We will never know in this poor patient's case what would have happened if she had just stayed on our treatment. Perhaps she would be exactly as sick as she is now. But it looked like she was getting better, as eleven out of fourteen of our patients have done the past two summers. Now she has full-blown viral encephalitis, and the eventual outcome does not look good. "
The patient's initial serum test for West Nile virus was negative, as is usually the case, so she has not yet been reported to the health authorities. A convalescent serum titer will be drawn in several weeks to see if she has WNV.
ABOUT GENOMED
GenoMed is a Next Generation DM(tm) [Disease Management] company that uses molecular medicine to improve patient outcomes and thus lower healthcare costs. Although the Company has effective treatments, there are obstacles to their adoption, as illustrated by this example. Currently, the company is marketing its protocols for preventing kidney failure from diabetes and high blood pressure, and significantly delaying emphysema.
GenoMed is conducting a free trial for WNV for the third consecutive summer. Those interested in participating are invited to download the trial documents from the Company's home page at www.genomed.com
. |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 6/29/2005 10:00:39 AM | | | | | | GenoMed CEO Testifies Before Missouri Medicaid Reform Commission
Contact: David Moskowitz MD FACP GenoMed, Inc. dwmoskowitz@genomed.com tel. 314-983-9933
ST. LOUIS--(June 29, 2005)--GenoMed Inc. ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol GMED) announced today that its CEO, David Moskowitz MD, has been invited to testify today, the first day of public testimony, before the Missouri Medicaid Reform Commission. The Medicaid Reform Commission is a joint committee of the Missouri House and Senate empanelled to study ways to rein in rising healthcare costs for the Missouri state Medicaid program.
As a first attempt, the Missouri Legislature cut 65,000 patients from the state Medicaid program this spring. These patients lose coverage on July 1st, i.e. this Friday. Since oxygen tanks are among the items no longer covered, many patients will soon die.
Said Dr. Moskowitz, "I'm honored to represent GenoMed and the promise of genomics-based medicine at the very first session of public testimony before the Missouri Medicaid Reform Commission. I'm happy to describe the dramatic cost-savings that Next Generation Disease Management can yield, as I did last week for the AFL-CIO Healthcare Taskforce in Washington, DC. My earnest hope is that Missouri legislators will consider adopting our protocols and stop the disenrollments before a single patient has died."
Added Dr. Moskowitz, "The Missouri Legislature is wrestling with the most critical domestic issue of our time. It is literally a life and death issue for tens of millions of Americans. It seems to me profoundly un-American, on the eve of our nation's birthday, to have people die simply because Medicaid is still paying retail for drugs. The best way to control healthcare costs is to control diseases and cut back on hospitalizations. Only genomics-based medicine can do this. And only GenoMed has demonstrated that it can halt cardiovascular diseases including emphysema."
About GenoMed
GenoMed, Inc. is a Next Generation DM(TM) company whose mission is to improve patient outcomes by identifying the molecular pathways that cause disease. DM (Disease Management) is the only healthcare player whose business model is to profit by lowering healthcare costs. A St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) first reported that the company applied for patents based on its finding that the ACE gene is associated with many common diseases. The company is currently marketing its protocols for preventing kidney failure due to diabetes and high blood pressure, and delaying the progression of emphysema.
. |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 7/13/2005 10:36:22 AM | | | | | | GenoMed Joins International Disease Management Alliance
ST. LOUIS--(July 13, 2005)--GenoMed Inc. ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol GMED) announced today that it has joined the International Disease Management Alliance (IDMA) recently organized by Warren E. Todd, the group's founder and Executive Director.
The IDMA (www.dmalliance.org) was formed to promote the concept of Disease Management around the world. As the only healthcare strategy that both improves patient outcomes and reduces healthcare costs, Disease Management has as much appeal globally as it does in the United States.
Said Warren E. Todd, Executive Director for IDMA, "We're delighted to welcome GenoMed to the Alliance and applaud their recognition of the international potential for disease management . Genomics provides a differentiated approach to disease management that should be well received in countries where more physician-centric models of disease management are common."
GenoMed's CEO, David Moskowitz MD, said, "We are thrilled to be one of the first Institutional members of the new IDMA and look forward to supporting the global expansion. Warren Todd is famous as one of the founders of the Disease Management industry in the U.S., and now around the world. We've long believed that our Next Generation DM(tm) business model would resonate especially well with capitated health plans, such as National Health Services in Canada, Europe, Japan, the United Kingdom, and other Commonwealth countries. GenoMed's membership in the IDMA should provide us with an entree to the global healthcare market. Our reliance on the Internet rather than telephone call centers, and our novel physician-oriented business model, give us a global reach immediately."
Added Dr. Moskowitz, "Rising healthcare costs have already reached a crisis point in the U.S. Medicaid programs in many states have begun disenrolling patients to lower costs. Many of these patients will soon die for lack of medications. The best way to control healthcare costs is to control diseases and cut back on hospitalizations. Only genomics-based medicine can do this. And only GenoMed has demonstrated that it can halt cardiovascular diseases including emphysema."
About GenoMed
GenoMed, Inc. is a Next Generation DM(TM) company whose mission is to improve patient outcomes by identifying the molecular pathways that cause disease. A St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) first reported that the company applied for patents based on its finding that the ACE gene is associated with many common diseases. The company is currently marketing its protocols for preventing kidney failure due to diabetes and high blood pressure, and delaying the progression of emphysema.
Contact:
David Moskowitz MD FACP
GenoMed, Inc.
dwmoskowitz@genomed.com
tel. 314-983-9933
. |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: jmhollen who wrote (271) | 7/27/2005 2:46:56 PM | | From: Tadsamillionaire | | | | GenoMed Submits 50th Provisional Patent
ST. LOUIS, July 26 /PRNewswire-FirstCall/ -- GenoMed Inc. ('the Company' or 'GenoMed') (Pink Sheets: GMED) announced today that the Company has submitted its 50th provisional patent application, a major milestone in any development stage company. GenoMed has so far been awarded two patents, one for treating acute kidney failure without dialysis, and another for hastening lung maturation in prematurely born infants.
Two of the most recently submitted patent applications include a drug delivery system whereby the delivery of drugs to the bloodstream is controlled through specially formulated toothpastes, and a method to reduce scarring and fibrosis both on the skin and in internal organs.
Small proteins like insulin don't survive the strong acid environment of the stomach, and must be injected to get into the bloodstream. As a result, patients with diabetes have to inject themselves under the skin one to three times a day. Putting insulin in toothpaste may be an effective method to get insulin into the bloodstream directly, especially after flossing, which often causes bleeding of the gums. It may be especially useful for patients with juvenile-onset diabetes, who must begin injecting insulin as pre-teens.
GenoMed's method to reduce scarring, both on the skin and in internal organs, involves another novel use for angiotensin I-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) either as pills, which already exist, or as topical creams. This approach may be useful in dermatology and plastic surgery, especially for burn victims who get extensive scarring, patients with keloid scars, etc.
GenoMed is currently looking for partners to help develop its toothpaste drug delivery system, as well as patients with scars or fibrosis of internal organs for clinical trials. Please contact GenoMed's CEO and Chief Medical Officer, David Moskowitz MD, at dwmoskowitz@genomed.com. |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| From: jmhollen | 8/22/2005 4:06:22 PM | | | | | | GenoMed Adds Dr. Richard Reece to Business Development Advisory Board
FOR IMMEDIATE RELEASE
Contact:
David Moskowitz MD FACP
GenoMed, Inc.
dwmoskowitz@genomed.com
tel. 314-983-9933
ST. LOUIS--(August 22, 2005)--GenoMed Inc. ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets symbol GMED) announced today the addition of Dr. Richard Reece, a prolific and influential medical writer, to its Business Development Advisory Board.
Dr. Richard Reece is a pathologist, writer, editor, and author. He has served as editor-in-chief of Physician Practice Options, a monthly newsletter for practicing physicians for nine years. The newsletter has variations that reach cardiologists, nephrologists, and oncologists. He is the author of four books. The latest is Voices of Health Reform (Practice Support Resources, Inc, 2005) consisting of 41 interviews with leading health care authorities. He also writes frequently for Healthleaders.com, which is read by 50,000 health care leaders each day. He serves on the advisory boards of the Center for Practical Health Reform and America's Top Doctors, a 1300 page book listings America's top doctors, based on nominations of other doctors.
Said Dr. David Moskowitz, GenoMed's Chairman and CEO, "Dr. Reece is a leader in developing practical approaches to health care reform, including consumer-directed healthcare. We are honored to have his help in crafting and delivering GenoMed's message of cost control and quality improvement to medical societies, health plans, and business coalitions."
About GenoMedTM
GenoMed, Inc. is a Next Generation DMTM company whose mission is to improve patient outcomes by identifying the molecular pathways or genes that cause disease. A St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) first reported that the company applied for patents based on its finding that the ACE gene is associated with many common diseases. The company is currently marketing its protocols for preventing kidney failure due to diabetes and high blood pressure, and delaying the progression of emphysema. The company is also conducting a free clinical trial for West Nile virus; to enroll, simply click on the West Nile virus link at www.genomed.com
. |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 8/24/2005 7:01:06 PM | | | | | | GenoMed™ Adds IT Experts to Business Development Advisory Board
Contact: David Moskowitz MD FACP GenoMed, Inc. dwmoskowitz@genomed.com tel. 314-983-9933
ST. LOUIS--(August 24, 2005)--GenoMed Inc. ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets symbol GMED) today announced the addition of IT experts Jack Gruninger and Chris Todd to its Business Development Advisory Board.
Jack Gruninger has over 15 years of experience in leading advanced Information Technology projects in the commercial and government sectors. He is currently Vice President – Technology for L-3 Communications Titan Corporation, founder of TapHere! Technology LLC, member of the Technology Advisory Board for the International Disease Management Association, and previously served as CTO for Brainbench.com.
Mr. Gruninger has provided technical presentations for many industry-leading technology conferences/seminars including the International Sybase Users Group, Professional Association for SQL Server, US Armed Forces Decision AIDS Conference, Armed Forces Communications & Electronics Association, and the Global Command & Control System Functional Working Group.
Chris Todd currently serves as Senior Software Engineer at L-3 Communications Titan Corporation, Vice President – Multimedia for TapHere! Technology LLC, and is a member of the Technology Advisory Board for the International Disease Management Association.
Mr. Todd has been a pioneer in commercial web technology and has extensive experience with leading-edge software/hardware design, database development, object-oriented programming, Internet / networking operations, optics, and multimedia. He has designed and developed over 30 enterprise-class, multi-tier software applications, many of which are deployed for operations and collaboration among leading health care organizations.
Said Dr. David Moskowitz, GenoMed's Chairman and CEO, "Our business relies entirely on the World Wide Web. Jack Gruninger and Chris Todd are experts in designing websites, adding multimedia content—video and audio--to websites, and making websites easy to find by search engines. To increase our revenue stream, we need a website that's easy for America's 80 million patients with diabetes and high blood pressure, and 5 million patients with emphysema, to find—not to mention the hundreds of millions of patients with these diseases worldwide."
About GenoMed™
GenoMed, Inc. is a Next Generation DM™ company whose mission is to improve patient outcomes by identifying the molecular pathways that cause disease. The company is currently marketing its protocols for preventing kidney failure due to diabetes and high blood pressure, and delaying the progression of emphysema. The company is also conducting a free clinical trial for West Nile virus; to enroll, simply click on the West Nile virus link at www.genomed.com
. |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 9/1/2005 3:13:57 PM | | | | | | GenoMed Scores 13th Victory Treating Neuroinvasive West Nile Virus in Humans
Contact: David Moskowitz MD GenoMed, Inc. tel. 314-983-9933 dwmoskowitz@genomed.com
ST. LOUIS—September 1, 2005--GenoMed Inc.-- ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol: GMED) a St. Louis, Missouri-based Next Generation Disease Management company, announced today that it successfully treated its thirteenth patient with presumed West Nile virus encephalitis.
The patient is a previously healthy man from Aberdeen, South Dakota who developed fever and headache and was diagnosed by his physician as having West Nile virus on Monday of this week. South Dakota has about 50 times higher incidence of West Nile virus this summer than California.
The patient found GenoMed on the Internet, and within 2 hours his physician had started him on an angiotensin II receptor blocker, GenoMed's patent-pending approach to most viral diseases, including West Nile virus. The patient's headache intensified over the next 24 hours, requiring a visit to the Emergency Room, where he was offered a spinal tap, but not hospitalized. The patient went home and slept most of the following day. He awoke in the afternoon without a high fever or neck stiffness any more.
David Moskowitz MD, FACP, GenoMed's Chief Medical Officer and CEO, commented, "This patient demonstrated an extremely rapid resolution of his symptoms, several days faster than expected. Our treatment failed to prevent progression to meningitis, which we've seen before, but it did result in an extremely rapid recovery thereafter, within the next 24 hours. The patient could just as easily have progressed to full-blown coma, which was a concern the night he went to the ER. Normally it takes 3-6 days to recover from West Nile virus meningo-encephalitis. This patient's total recovery time was a bit under 48 hours, and under 24 hours from his worst symptoms of neck stiffness or meningitis."
During the past three summers, GenoMed has treated 16 patients, of whom this patient represents the 13th treatment success (81%). GenoMed has had a 50% treatment success rate in birds, and is eager to treat horses, also.
To enroll in GenoMed's free clinical trial, which uses already existing, safe medication present in every drug store and hospital, just go to www.genomed.com and click on the link for the West Nile virus trial.
About GenoMed
GenoMed has found what it believes to be the "master" disease gene, and has already been able to prevent kidney failure due to diabetes and hypertension in whites, blacks and Hispanics; dramatically delay the progression of terminal emphysema; and begin to see success in treating autoimmune diseases, West Nile virus encephalitis, and cancer. GenoMed's broad-spectrum anti-viral approach was specifically mentioned in BioShield II, recently introduced in the US Senate (see Section 2151 of Senate bill S. 975). GenoMed has recently found several thousand genes for the top six solid cancers in Caucasians--breast, colon, lung, ovarian, pancreatic, and prostate--and is currently offering its Healthchip(r) for early diagnosis of cancer on a research basis.
. |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: jmhollen who wrote (276) | 9/7/2005 10:26:10 AM | | From: Tadsamillionaire | | | | The World Health Organisation (WHO) repeated a warning that bird flu had spread from farm poultry to migratory birds which could spark a pandemic.
WHO director general Lee Jong-wook warned Asian health ministers meeting in Colombo that there was a fresh threat of the virus spreading quickly.
"He cautioned them about a possible impending Avian influenza pandemic," the Geneva-based organisation said in a statement after the two-day meeting.
"Dr. Lee said that the reservoir of the virus had moved from domestic poultry to ducks and has now been established in migratory birds in China. The danger of the expanding geographical range of the virus increases possibility for human cases to occur, increasing the potential for it to become more contagious."
The organisation said Asian countries at risk needed to improve efforts at case detection to ensure an early warning to others, mobilise international stockpiles of antiviral drugs and speed up vaccine manufacturing capacity.
Other experts have previously said wild birds were spreading avian influenza, known as H5N1, far beyond its epicentre in the backyard farms of Asia.
But scientists have argued over the disease transmission path, which most recently saw it spread to parts of Russia and Kazakhstan and prompted warnings it could next move into Europe and South Asia.
Two Asia-based British ornithologists this week refuted the theory the virus was spread by migratory birds.
Martin Williams, an ornithologist in Hong Kong, and fellow bird watcher Nial Moores in South Korea, say their studies show the spread of bird flu does not match with migration patterns of wild birds in Asia.
Asia has been battling bird flu since late 2003, with vaccination campaigns and massive culls of tens of millions of chickens and ducks that have devastated poultry industries, particularly in Thailand and Vietnam.
Bird flu has killed 62 people in Asia in the past two years, including 43 in Vietnam.
news.yahoo.com |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Tadsamillionaire | 9/8/2005 4:25:47 PM | | | | | | GenoMed Offers New Orleans Free Medical Assistance for Acute Kidney Failure and Mosquito-borne Viral Diseases like West Nile
GenoMed, Inc. ("the Company" or "GenoMed") (Pink Sheets: GMED - News) a St. Louis, Missouri-based Next Generation Disease Management company, announced today that it was offering free assistance to medical workers confronting acute kidney failure in the wake of Hurricane Katrina in Louisiana, Mississippi, and Alabama. In future weeks, the Company stands ready to help with the expected resurgence in West Nile virus encephalitis and the possible emergence of other mosquito-borne viral diseases like dengue, St. Louis Equine Encephalitis, etc.
Many patients in New Orleans and elsewhere in Katrina's path are at imminent risk for acute kidney failure from dehydration, brought on by excessive heat and the lack of drinking water. With power gone in the hurricane zone, patients will need to be air-lifted to nearby dialysis facilities. Tens of thousands of people are at risk, far more than can be accommodated this way. A method for treating acute kidney failure without dialysis is urgently needed.
GenoMed was recently awarded a patent to treat acute kidney failure with an already existing intravenous medication which has been available for decades. In pilot studies, GenoMed's method has avoided the need for kidney dialysis in over 70% of adults and infants tested.
biz.yahoo.com |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| |
